{"nctId":"NCT01214915","briefTitle":"Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia","startDateStruct":{"date":"2010-10-27","type":"ACTUAL"},"conditions":["Essential Thrombocythemia (ET)"],"count":53,"armGroups":[{"label":"Anagrelide Hydrochloride","type":"EXPERIMENTAL","interventionNames":["Drug: Anagrelide Hydrochloride"]}],"interventions":[{"name":"Anagrelide Hydrochloride","otherNames":["SPD422"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have previously been treated with a cytoreductive therapy and been intolerant or refractory to that therapy.\n\nExclusion Criteria:\n\n* Subjects should not have any other underlying conditions or medications that would confound the study analysis or interact with the study medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Responded in Platelet Count","description":"A response was defined as platelet counts to \\<600x10\\^9/L across consecutive visits for at least 4 weeks following at least 3 months of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With at Least 50% Reduction in Platelet Count","description":"Subjects who achieved at least 50% reduction in platelet count from their baseline level across consecutive visits for at least 4 weeks and following 3 months of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Normalization in Platelet Count","description":"Normalization was defined as platelet counts ≤400x10\\^9/L across consecutive visits for at least 4 weeks following at least 3 months of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Responded in Platelet Count Whose Baseline Platelet Count Was ≥600x10^9/L","description":"A response was defined as platelet counts to \\<600x10\\^9/L across consecutive visits for at least 4 weeks following at least 3 months of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Responded in Platelet Count Whose Baseline Platelet Count Was <600x10^9/L","description":"A response was defined as platelet counts to \\<600x10\\^9/L across consecutive visits for at least 4 weeks following at least 3 months of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":53},"commonTop":["ANAEMIA","HEADACHE","PALPITATIONS","DIARRHOEA","OEDEMA PERIPHERAL"]}}}